CLS enters subscription undertakings and guarantee commitments for the redemption of warrants of series TO 7 B

Clinical Laserthermia Systems AB ("CLS" or the "Company") announces that the Company has entered into agreements of subscription undertakings and guarantee commitments (so-called "top-down guarantee") for the upcoming redemption of warrants of series TO 7 B ("TO 7 B”). The redemption period begins on November 11, 2024. The subscription undertakings and the guarantee commitment have mainly been entered into by the Company's largest shareholder, among them Khattar Holdings, and comprise a total of approximately 14.5% of the number of outstanding warrants and guarantee commitments of approximately SEK 5.4 million.

Prior to the redemption of TO 7 B, CLS has entered into subscription undertaking agreements with a number of the Company's major existing owners corresponding to approximately 15% of the number of outstanding warrants as well as a top guarantee from both existing and external investors of approximately SEK 5.4 million. The Company's largest shareholder, among them Khattar Holdings, have entered into subscription undertaking agreements for their respective pro rata shares and participate in the guarantee with a total of SEK 3 million.

 

"Khattar Holdings is unwavering in its support of CLS and its team on the journey towards realizing the potential of its unique product offerings. Our commitments to the upcoming redemption of warrants are simply an extension of our confidence in the Company and the progress and strategic initiatives recently communicated." says Navin Khattar of Khattar Holdings Private Limited.

 

"I am of course very positive about the strong support we have from our major existing shareholders in the redemption of warrants. With the upcoming proceeds, we strengthen the Company's cash position and continue the announced restructuring of our commercial operations, with a focus entirely on neurosurgery, and with increased cost savings. I warmly welcome the other warrant holders to also participate in the redemption of warrants in November." says Dan J. Mogren, CLS CEO.

 

The guarantee commitments constitutes a so-called "top-down guarantee". The guarantee commitment is thus added to the final subscription level for TO 7 B and is intended to ensure the last part of the exercise in the redemption of warrants in the event that all TO 7 B are not exercised by existing warrant holders. If the board of the Company decides to claim the guarantee undertaking, this will be done through a directed issue of shares to the guarantors at a subscription price corresponding to the exercise price for TO 7 B. For the guarantee undertaking, a compensation of 10% will be paid in shares to existing shareholders, as well as a compensation of 10% will be paid in shares or cash for external investors. No compensation is paid for the subscription undertakings. The guarantee compensation has been determined through negotiations between the Company and the guarantors at arm’s length. The board considers the compensation to be in line with market terms. Neither subscription undertakings nor guarantee undertakings are secured by bank guarantee, blocked funds, pledges or similar arrangements.

 

Warrants of series TO 7

One (1) warrant will entitle the holder to subscribe for one (1) new B-share in the Company at a subscription price corresponding to 70 percent of the volume-weighted average price of the Company’s B-share on Nasdaq First North Growth Market during a period of ten (10) trading days before, and including, 7 November 2024, however not lower than the share’s quota value of SEK 2.31 and not higher than SEK 9. The exercise period will run between 11 and 22 November 2024. Full terms and conditions for the warrants are available on CLS website, www.clinicallaser.se.

 

Advisers

Redeye AB is acting as financial adviser and Foyen Advokatfirma is acting as legal adviser to CLS in connection with the exercise of warrants series TO 7 B. Nordic Issuing AB is acting as issuing agent.

 

For more information, please contact

Dan J Mogren, CEO Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-mail: [email protected]

 

 

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se

This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-10-2024 08:30 CET.